Muscarinic acetylcholine receptors (mAChRs) are G-protein-coupled receptors (GPCRs) belonging to the rhodopsin superfamily. Five subtypes, designated M1 (muscarinic receptor 1) through M5 (muscarinic receptor 5), are encoded by five distinct genes and differ in their G-protein coupling preferences, second messenger systems, tissue distributions, and physiological roles. All five subtypes are activated by acetylcholine (ACh) and blocked by atropine; selectivity among subtypes is exploited therapeutically by agents targeting specific organs while minimizing systemic cholinergic side effects.
M1 Receptors. M1 muscarinic receptors (M1 mAChRs) couple to Gq/11 proteins, activating phospholipase C beta (PLC-beta), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium (Ca2+) release from the endoplasmic reticulum, and DAG activates protein kinase C (PKC), together producing cellular excitation. M1 receptors predominate in the cerebral cortex, hippocampus, and striatum, where they modulate cognitive function, memory encoding, and striatal dopamine signaling. They are also highly expressed in peripheral autonomic ganglia, where they mediate the slow excitatory postsynaptic potential (slow EPSP) that modulates ganglionic transmission. In the gastric parietal cells, M1 receptor activation contributes to acid secretion. Drugs with relative M1 selectivity include pirenzepine (used for peptic ulcer disease in some countries to reduce gastric acid), and selective M1 agonists are under investigation for Alzheimer disease to enhance cortical cholinergic tone without the peripheral side effects of non-selective agents.1
Muscarinic Type 2 (M2) Receptors. M2 mAChRs couple to Gi/Go proteins, which inhibit adenylyl cyclase (AC), reduce cyclic adenosine monophosphate (cAMP) formation, and activate G-protein-coupled inwardly rectifying potassium (GIRK) channels. In the heart, M2 receptor activation by vagal ACh at the sinoatrial (SA) node slows heart rate (negative chronotropy) by hyperpolarizing the pacemaker cells through GIRK channel activation; at the atrioventricular (AV) node, M2 activation slows conduction velocity (negative dromotropy). In ventricular myocardium, M2 receptors attenuate beta-adrenergic-stimulated contractility by reducing cAMP. M2 receptors also function as presynaptic autoreceptors on parasympathetic terminals (inhibiting further ACh release) and as presynaptic heteroreceptors on sympathetic terminals (inhibiting NE release), constituting a point of sympathetic-parasympathetic interaction at the terminal level. The anticholinergic drugs used in bradyarrhythmias and organophosphate poisoning (atropine, glycopyrrolate) produce their cardiac effects predominantly through M2 receptor blockade.2 Selective M2 antagonists are under development as potential cognitive enhancers, since presynaptic M2 autoreceptors in the brain limit ACh release.14
M3 Receptors. Muscarinic M3 receptors (M3 mAChRs) couple to Gq/11 (same as M1) and activate PLC-beta, generating IP3 and DAG to mobilize intracellular Ca2+ and activate PKC. Despite sharing the M1 signaling pathway, M3 receptors have distinct tissue distribution: they are the dominant muscarinic subtype in smooth muscle and exocrine glands. In bronchial smooth muscle, M3 activation produces bronchoconstriction by increasing intracellular Ca2+, which activates myosin light chain kinase (MLCK); this is the target of anticholinergic bronchodilators used in chronic obstructive pulmonary disease (COPD) and asthma. In the gastrointestinal (GI) tract, M3 receptors mediate smooth muscle contraction and secretion. In the urinary bladder detrusor muscle, M3 activation produces contraction (voiding); drugs blocking M3 receptors in the bladder (oxybutynin, solifenacin, darifenacin, tolterodine, trospium, fesoterodine) reduce overactive bladder symptoms. In salivary and lacrimal glands, M3 receptors drive secretion; M3 blockade produces the dry mouth and dry eyes common to all non-selective anticholinergics. In vascular endothelium, M3 receptor activation stimulates nitric oxide (NO) synthase, producing vasodilation through endothelium-dependent mechanisms.13
M4 and M5 Receptors. Muscarinic M4 receptors (M4 mAChRs) couple to Gi/Go (like M2), inhibiting adenylyl cyclase and reducing cAMP. They are expressed predominantly in the striatum and basal ganglia, where they modulate dopaminergic transmission; M4 autoreceptors on cholinergic interneurons provide feedback inhibition of ACh release and influence the balance between cholinergic and dopaminergic tone in the striatum. This interaction is clinically relevant to Parkinson disease, where loss of dopaminergic input shifts the striatal cholinergic-dopaminergic balance toward excess cholinergic activity, accounting for the therapeutic benefit of anticholinergic agents (benztropine, trihexyphenidyl) in reducing tremor. M4 is also expressed in the dorsal horn of the spinal cord, where it may modulate pain processing. M5 mAChRs couple to Gq/11 and are expressed at very low levels, primarily in the substantia nigra and ventral tegmental area (VTA), where they modulate dopamine neuron excitability. M5 is the only muscarinic subtype expressed in dopaminergic neurons of the mesolimbic pathway, and experimental evidence suggests that M5 receptors mediate ACh-induced potentiation of dopamine release in the nucleus accumbens; M5 antagonism is under investigation as a potential target for substance use disorders. No clinically available drugs are M4- or M5-selective.14
M1 (Gq/11): cerebral cortex, hippocampus, ganglia, gastric parietal cells. Blocked by pirenzepine (gastric acid). M2 (Gi/Go): heart SA/AV nodes (cardiac), presynaptic autoreceptors (neural). Atropine produces tachycardia via M2 blockade. M3 (Gq/11): smooth muscle, exocrine glands, vascular endothelium, bladder detrusor. Bronchodilators (ipratropium, tiotropium) block M3 in airways. Bladder antimuscarinics block M3 (solifenacin, darifenacin) and M2 in bladder. M4 (Gi/Go): striatum, dorsal horn. Benztropine/trihexyphenidyl: M1/M4 block in basal ganglia → Parkinson tremor. M5 (Gq/11): substantia nigra, VTA; no selective clinical agents yet.
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels (LGICs) belonging to the Cys-loop receptor superfamily. Unlike the GPCRs of the muscarinic class, nAChRs mediate fast synaptic transmission by directly gating a cation channel permeable to Na+, K+, and Ca2+ upon ACh binding. Two principal subtypes are pharmacologically distinguished by their subunit composition, location, and sensitivities to blocking agents: the neuromuscular subtype (NM) at the skeletal muscle end-plate and the neuronal subtype (NN) at autonomic ganglia and in the central nervous system (CNS).
Ion Channel Architecture. All nAChRs are pentamers assembled from subunits chosen from a family of at least 17 known subunit genes (alpha 1–10, beta 1–4, gamma, delta, epsilon). Each subunit has four transmembrane domains (TM1 through TM4); the second transmembrane segment (TM2) from each of the five subunits lines the channel pore, creating the ion-selective gate. Each receptor contains two ACh-binding sites located at interfaces between alpha subunits and adjacent subunits; both sites must be occupied for efficient channel opening. Channel opening allows Na+ influx and K+ efflux down their electrochemical gradients, producing end-plate depolarization within milliseconds. At the NM junction, Ca2+ entry through the channel is relatively limited; at neuronal nAChRs, Ca2+ permeability is substantially higher, contributing to intracellular signaling downstream of receptor activation. The rapid kinetics of nAChR gating and desensitization distinguish these receptors from the slower, amplified responses of G-protein-coupled receptor (GPCR)-linked muscarinic receptors.5
Neuromuscular Nicotinic Receptors (NM). The adult neuromuscular junction (NMJ) nAChR has the subunit composition alpha1(2):beta1:delta:epsilon (in fetal/denervated muscle, epsilon is replaced by gamma). This stoichiometry confers high sensitivity to ACh and to the NM-selective blocking agent d-tubocurarine, and low sensitivity to hexamethonium (a ganglionic blocker). Two classes of drugs block NM receptors clinically. Depolarizing neuromuscular blockers (NMBs), exemplified by succinylcholine, are ACh receptor agonists that first activate the receptor (producing fasciculations from transient muscle depolarization) and then prevent repolarization by maintaining persistent end-plate depolarization; because the channel is held open and inactivated, further ACh cannot produce contraction. Succinylcholine is hydrolyzed by butyrylcholinesterase (BuChE) and has an ultra-short duration of action of approximately 5 to 10 minutes under normal circumstances. Non-depolarizing NMBs (rocuronium, vecuronium, cisatracurium, atracurium, pancuronium) are competitive antagonists that occupy the ACh-binding sites without activating the channel, producing competitive blockade reversible by AChE inhibitors (neostigmine, sugammadex for rocuronium/vecuronium specifically). Phase II block (desensitization block) may occur with prolonged succinylcholine infusion, mimicking non-depolarizing blockade and requiring AChE inhibitors for reversal.56
Neuronal Nicotinic Receptors (NN). Autonomic ganglionic nAChRs are predominantly composed of alpha3:beta4 subunits (with accessory alpha5 and beta2 subunits in some populations). This composition confers sensitivity to hexamethonium, trimethaphan, and mecamylamine (ganglionic blockers) and relative insensitivity to NM-selective agents. Ganglionic transmission serves all preganglionic-to-postganglionic synapses in both the sympathetic and parasympathetic nervous systems; complete ganglionic blockade therefore produces profound mixed autonomic paralysis. Trimethaphan and mecamylamine were used as antihypertensives in the mid-twentieth century; trimethaphan retains a niche use for hypertensive emergencies associated with aortic dissection, where rapid ganglionic blockade reduces both blood pressure and the force of cardiac contraction (dP/dt), limiting aortic stress. CNS nAChRs contain alpha4:beta2 (the most abundant brain subtype, mediating nicotine dependence and targeted by varenicline, a partial agonist used for smoking cessation) and homomeric alpha7 receptors (high Ca2+ permeability, implicated in attention, memory, and neuroinflammation).7
Depolarizing (succinylcholine): Agonist at NM; fasciculations then flaccid paralysis; not reversed by neostigmine (can worsen Phase I block); reversed by BuChE hydrolysis; complications include hyperkalemia (avoid in burns, denervation, crush injury, prolonged immobility), malignant hyperthermia trigger, bradycardia. Non-depolarizing (rocuronium, vecuronium, cisatracurium): Competitive antagonist at NM; no fasciculations; reversed by neostigmine (AChE inhibition) or sugammadex (encapsulates rocuronium/vecuronium selectively); cisatracurium undergoes Hofmann elimination (organ-independent degradation, preferred in hepatic/renal failure). Train-of-four (TOF) monitoring differentiates block type: fade present with non-depolarizing; no fade (all twitches equal) with Phase I depolarizing block.
Adrenergic receptors (ARs) are G-protein-coupled receptors (GPCRs) activated by norepinephrine (NE) and epinephrine (epi). Five main subtypes are defined by their G-protein coupling, signal transduction mechanisms, tissue distribution, and sensitivity to selective agonists and antagonists. The clinical pharmacology of catecholamines, vasopressors, bronchodilators, antihypertensives, and heart failure therapy follows directly from understanding which adrenergic receptor (AR) subtype mediates each organ response and which drugs engage those subtypes selectively.
Alpha-1 Adrenergic Receptors. Alpha-1 adrenergic receptors (alpha-1 ARs) couple to Gq/11, activating phospholipase C beta (PLC-beta) to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 releases intracellular Ca2+ from the sarcoplasmic reticulum, and DAG activates protein kinase C (PKC). In vascular smooth muscle, this signaling produces contraction and vasoconstriction, the dominant vascular effect of NE and the primary mechanism of action of vasopressors such as phenylephrine (alpha-1 selective) and norepinephrine (alpha-1 and beta-1). In the iris dilator muscle, alpha-1 activation produces mydriasis. In the urinary bladder neck and internal urethral sphincter, alpha-1 activation produces contraction, maintaining urinary continence; selective alpha-1A antagonists (tamsulosin, silodosin) relax the prostate and bladder neck smooth muscle in benign prostatic hyperplasia (BPH) with minimal vascular effects. Alpha-1 AR blockade (prazosin, terazosin, doxazosin) produces vasodilation and is used in hypertension and BPH. Phentolamine and phenoxybenzamine are non-selective alpha blockers (also block alpha-2) used in pheochromocytoma; phenoxybenzamine is irreversible (alkylating agent) while phentolamine is competitive and short-acting. Alpha-1 AR activation also produces pilomotor muscle contraction (gooseflesh), which is clinically exploited in opioid withdrawal assessment.8
Alpha-2 Adrenergic Receptors. Alpha-2 ARs couple to Gi/Go, inhibiting adenylyl cyclase and reducing cAMP, and activating G-protein-coupled inwardly rectifying potassium (GIRK) channels to hyperpolarize the cell. Three subtypes exist: alpha-2A predominates in the central nervous system (CNS) locus coeruleus (where it mediates sedation, analgesia, and sympatholysis), alpha-2B is the main vascular postsynaptic alpha-2 AR mediating vasoconstriction at high NE concentrations, and alpha-2C is expressed in the striatum. Presynaptically, alpha-2 ARs on sympathetic terminals provide negative feedback inhibition of NE release, setting the gain of sympathetic tone. Postsynaptically in blood vessels, alpha-2 activation produces vasoconstriction (particularly in venous and splanchnic circulation). Clinically, centrally acting alpha-2 agonists (clonidine, guanfacine, methyldopa, dexmedetomidine) reduce sympathetic outflow from the brain, producing antihypertensive and sedative effects. Dexmedetomidine is a highly selective alpha-2A agonist used for ICU sedation and procedural sedation; it produces sedation and analgesia without respiratory depression, because alpha-2A ARs in the locus coeruleus mediate sedation while the mu-opioid receptors of the brainstem respiratory centers are unaffected. Clonidine is also used for ADHD (children), opioid withdrawal, and menopausal hot flashes. Yohimbine and atipamezole are alpha-2 AR antagonists.89
Beta-1 Adrenergic Receptors. Beta-1 ARs couple to Gs, stimulating adenylyl cyclase to increase cAMP, which activates protein kinase A (PKA). PKA phosphorylates multiple cardiac targets: L-type Ca2+ channels (increasing Ca2+ influx, positive inotropy), phospholamban (relieving inhibition of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump in its cardiac 2a isoform, accelerating diastolic Ca2+ reuptake and improving lusitropy), the ryanodine receptor (increasing Ca2+ release from the sarcoplasmic reticulum), troponin I (reducing myofilament Ca2+ sensitivity, accelerating relaxation), and the sinoatrial (SA) nodal funny current (If) and L-type channels (positive chronotropy). Beta-1 ARs are the dominant adrenergic receptor in the ventricular myocardium and SA node, making them the principal cardiac adrenergic receptor. Beta-1-selective agonists (dobutamine) increase cardiac output in acute decompensated heart failure. Beta-1-selective antagonists (metoprolol, atenolol, bisoprolol, esmolol) reduce heart rate and myocardial oxygen demand; they are used in heart failure (to reverse chronic sympathetic overstimulation-induced downregulation), hypertension, rate control in atrial fibrillation, and acute coronary syndromes. Esmolol has an ultra-short duration (half-life approximately 9 minutes) due to red blood cell esterase hydrolysis, making it useful for acute intraoperative rate control.610
Beta-2 Adrenergic Receptors. Beta-2 ARs also couple to Gs and raise cAMP via adenylyl cyclase, but their tissue distribution differs from beta-1. They are the dominant beta-AR in bronchial smooth muscle, where cAMP-mediated PKA activation phosphorylates myosin light chain kinase (MLCK), reducing myosin light chain phosphorylation and producing bronchodilation. Beta-2 ARs are also expressed in skeletal muscle vasculature (producing vasodilation at epi concentrations achieved during adrenal activation), uterine smooth muscle (relaxation, used therapeutically as tocolytics to arrest premature labor), and in hepatic and skeletal muscle cells (where they mediate glycogenolysis and gluconeogenesis, contributing to the hyperglycemia of sympathetic activation). Beta-2 agonists used clinically include short-acting agents (salbutamol/albuterol, terbutaline, levalbuterol) and long-acting agents (salmeterol, formoterol, indacaterol) for asthma and chronic obstructive pulmonary disease (COPD). Systemic beta-2 activation at high doses produces tremor (skeletal muscle effect), tachycardia (through beta-1 cross-reactivity and reflex mechanisms), and hypokalemia (by driving K+ into cells). Beta-2 ARs in the vascular endothelium mediate vasodilation contributing to the hemodynamic profile difference between epinephrine (which reaches beta-2) and pure sympathetic neuronal NE (which does not).811
Beta-3 Adrenergic Receptors. Beta-3 ARs couple to Gs (and to Gi in some tissues) and are expressed predominantly in white and brown adipose tissue and in the urinary bladder detrusor muscle. In adipose tissue, beta-3 activation stimulates lipolysis and thermogenesis; in brown adipose tissue, it activates uncoupling protein 1 (UCP1), promoting non-shivering thermogenesis. Beta-3 ARs show substantially greater resistance to desensitization compared to beta-1 and beta-2 ARs, a property relevant to their role in sustained lipolysis during prolonged sympathetic activation. In the bladder detrusor, beta-3 AR activation produces relaxation (opposite to muscarinic M3 [M3]-mediated contraction), promoting urine storage. Mirabegron, a selective beta-3 AR agonist, is used for overactive bladder as an alternative to anticholinergic agents, offering the advantage of avoiding dry mouth, constipation, and cognitive effects associated with muscarinic blockade. Beta-3 AR agonists are also under investigation for metabolic syndrome and obesity, though no agents beyond mirabegron are yet clinically available in the United States.8
Alpha-1 (Gq/11 → PLC → IP3/DAG → Ca2+): vasoconstriction, mydriasis, urethral sphincter contraction. Agonists: phenylephrine, NE. Antagonists: prazosin/terazosin/doxazosin (hypertension/BPH), tamsulosin (BPH), phentolamine, phenoxybenzamine (pheo). Alpha-2 (Gi/Go → inhibit AC → decreased cAMP): presynaptic NE inhibition, central sympatholysis, vasoconstriction. Agonists: clonidine, guanfacine, dexmedetomidine, methyldopa. Beta-1 (Gs → AC → cAMP → PKA): positive chronotropy, inotropy, lusitropy in heart. Agonist: dobutamine. Antagonists: metoprolol, atenolol, bisoprolol, esmolol. Beta-2 (Gs → AC → cAMP → PKA): bronchodilation, uterine relaxation, skeletal muscle vasodilation. Agonists: albuterol, salmeterol, terbutaline (tocolytic). Beta-3 (Gs/Gi → cAMP): bladder detrusor relaxation, lipolysis, thermogenesis. Agonist: mirabegron (overactive bladder).
Dopamine receptors are GPCRs classified into two families based on their G-protein coupling and signal transduction: the excitatory family, or D1-like group (comprising dopamine-1 [D1] and dopamine-5 [D5] receptors, coupling to Gs) and the inhibitory family, or D2-like group (comprising dopamine-2 [D2], dopamine-3 [D3], and dopamine-4 [D4] receptors, coupling to Gi/Go). While dopamine receptors are best known for their role in central nervous system (CNS) neuropsychiatric pharmacology, they are also expressed in the periphery, including the kidney, mesenteric vasculature, sympathetic ganglia, and adrenal medulla, where they have therapeutically exploitable autonomic effects.
D1 and D5 Receptors (D1-Like Family). D1 dopamine receptors (D1 receptors) couple to Gs, stimulating adenylyl cyclase to increase cAMP and activating protein kinase A (PKA). D5 dopamine receptors (D5 receptors) share this signaling pathway but have higher affinity for dopamine than D1. In the kidney, D1 receptor activation on proximal tubular cells reduces Na+/K+-ATPase and Na+/H+ exchanger activity, promoting natriuresis; in the renal and mesenteric vasculature, D1 activation produces vasodilation by increasing cAMP in smooth muscle cells. Low-dose dopamine infusion (1 to 3 micrograms per kilogram per minute) activates predominantly D1 receptors in the renal and splanchnic vasculature, producing vasodilation and increased renal blood flow; however, clinical trials have not demonstrated that low-dose dopamine prevents acute kidney injury or improves outcomes in acutely ill patients, and the practice of renal-dose dopamine is no longer recommended in contemporary guidelines. Fenoldopam is a selective D1 receptor agonist used clinically for hypertensive emergencies; it produces renal vasodilation and natriuresis simultaneously with afterload reduction, making it useful in hypertensive emergencies with renal impairment.14 D5 receptors are expressed in the hypothalamus and limbic areas but have no selective clinical agents targeting them.13
D2 Receptors. D2 receptors couple to Gi/Go, inhibiting adenylyl cyclase, activating G-protein-coupled inwardly rectifying potassium (GIRK) channels, and reducing Ca2+ channel conductance. They are expressed presynaptically as autoreceptors on dopaminergic nerve terminals in the substantia nigra and striatum (where their activation decreases dopamine synthesis and release, providing feedback inhibition), and postsynaptically in the striatum, limbic system, pituitary, and peripheral sympathetic ganglia. In the anterior pituitary, D2 activation on lactotrophs inhibits prolactin secretion, explaining why D2 antagonists (antipsychotic drugs) raise prolactin levels and D2 agonists (bromocriptine, cabergoline) suppress prolactin in hyperprolactinemia and prolactinoma. In the chemoreceptor trigger zone (CTZ) of the area postrema, D2 activation stimulates vomiting; D2 antagonists (metoclopramide, prochlorperazine, haloperidol) are used as antiemetics through CTZ blockade. In peripheral sympathetic ganglia and the adrenal medulla, D2 receptors modulate catecholamine release through presynaptic inhibition.13
D3 and D4 Receptors. D3 receptors couple to Gi/Go (like D2) and are expressed predominantly in the limbic system, nucleus accumbens, hypothalamus, and olfactory tubercle. Their restricted limbic distribution has made them targets for antipsychotic drug development, with the hypothesis that D3-selective antagonism might reduce the positive symptoms of schizophrenia with less extrapyramidal risk than D2 blockade in the striatum. No D3-selective drug is currently in clinical use, but several atypical antipsychotics (amisulpride, cariprazine) have significant D3 affinity. D4 receptors also couple to Gi/Go and are expressed in the prefrontal cortex, amygdala, and pituitary. Clozapine, the prototype atypical antipsychotic, has high D4 affinity relative to D2, a property once proposed to explain its superior efficacy in treatment-resistant schizophrenia and its low extrapyramidal side effect burden; however, the precise contribution of D4 blockade to clozapine's clinical profile remains under investigation. In the autonomic context, D4 receptors modulate sympathetic ganglionic transmission but do not have specific clinical drug targeting at this time.1315
D1-like (D1, D5; Gs → increase cAMP): renal/mesenteric vasodilation, natriuresis. D1 agonist: fenoldopam (hypertensive emergency with renal involvement). Low-dose dopamine acts here but lacks evidence for renal protection. D2-like (D2, D3, D4; Gi/Go → decrease cAMP): inhibit prolactin (D2 agonists → bromocriptine/cabergoline for hyperprolactinemia, prolactinoma); anti-emesis via CTZ D2 blockade (metoclopramide, prochlorperazine); antipsychotics block D2 → extrapyramidal effects from striatal D2 blockade; higher D4/D2 ratio in clozapine → fewer extrapyramidal effects. D2 presynaptic autoreceptors → feedback inhibit dopamine synthesis; low-dose D2 agonists can reduce dopamine release (paradoxical effect exploited in some dyskinesia treatments).
Autonomic receptors are not static entities. Sustained activation by agonists or chronic blockade by antagonists produces adaptive changes in receptor number, coupling efficiency, and intracellular signaling that profoundly affect the clinical pharmacology of autonomic drugs. These phenomena explain tolerance to prolonged agonist therapy, rebound effects after abrupt drug withdrawal, the hemodynamic instability of denervated organs, and the delayed therapeutic effects of drugs that act through receptor regulation rather than acute receptor occupation.
Homologous Desensitization. Homologous desensitization refers to reduced receptor responsiveness produced by the receptor's own agonist, affecting only the activated receptor without altering the sensitivity of other receptor types in the same cell. The mechanism for GPCRs involves a sequence of phosphorylation and internalization events. When an agonist occupies a G-protein-coupled receptor (GPCR) such as a beta-2 adrenergic receptor (AR), the agonist-bound receptor conformation is preferentially phosphorylated by a family of G-protein-coupled receptor kinases, each called a GPCR kinase (GRK). GRK2 (beta-adrenergic receptor kinase 1) and GRK3 (beta-adrenergic receptor kinase 2) are the principal isoforms for beta-ARs. GRK-mediated phosphorylation recruits the scaffold protein beta-arrestin to the receptor, which sterically uncouples the receptor from its G protein (Gs), terminating cAMP generation even in the continued presence of agonist. Beta-arrestin-bound receptors are then internalized into endosomes by clathrin-coated vesicle machinery. Once internalized, receptors may be recycled back to the membrane (resensitization) or targeted for lysosomal degradation, reducing total receptor number (downregulation). In asthma and chronic obstructive pulmonary disease (COPD) management, prolonged use of short-acting beta-2 agonists has been associated with progressive desensitization and reduced bronchodilatory response; long-acting beta-2 agonists combined with inhaled corticosteroids mitigate desensitization in part because corticosteroids upregulate beta-2 AR gene transcription, replacing desensitized receptors.1116
Heterologous Desensitization. Heterologous desensitization involves reduced responsiveness of multiple receptor types in the same cell, not limited to the receptor bound by the agonist. This occurs through second-messenger-activated kinases, particularly protein kinase A (PKA) and protein kinase C (PKC), which phosphorylate G-protein-coupled receptors (GPCRs) at sites distinct from the GRK phosphorylation sites. For example, when beta-1 AR activation raises cAMP and activates PKA, the elevated PKA can phosphorylate and partially uncouple other GPCRs in the same myocyte that couple through Gs, including beta-2 ARs, even if those receptors have not been directly occupied by agonist. Similarly, activation of one Gq-coupled receptor raising diacylglycerol (DAG) and activating PKC can reduce the responsiveness of other Gq-coupled receptors in the same cell. Heterologous desensitization is less selective and less easily reversed than homologous desensitization, and it contributes to the complex pharmacodynamic interactions observed when multiple GPCR-targeting drugs are combined in the same patient. In heart failure, sustained elevation of sympathetic tone produces both homologous desensitization (GRK-mediated phosphorylation of beta-1 ARs) and heterologous desensitization (PKA-mediated uncoupling), which together reduce the cardiac response to catecholamines; beta-blocker therapy partially reverses this by reducing GRK activity and allowing receptor resensitization, which is one mechanism by which beta-blockers improve contractile function over weeks in heart failure patients despite acutely reducing contractility.1016
Receptor Downregulation and Upregulation. Sustained agonist exposure reduces total receptor protein through increased receptor degradation and decreased receptor gene transcription, a process called downregulation. In the failing heart, chronic sympathetic overactivation produces a 50 to 60% reduction in beta-1 AR density compared to the normal myocardium; this downregulation reduces the inotropic reserve of the failing heart and limits the effectiveness of acute catecholamine infusions. Chronic treatment with beta-blockers in heart failure partially restores beta-1 AR density over 3 to 6 months, contributing to the improvement in contractile function and exercise tolerance that defines the long-term benefit of beta-blocker therapy in heart failure with reduced ejection fraction (HFrEF). The inverse phenomenon, receptor upregulation, occurs after chronic receptor blockade or denervation. When a receptor is chronically unoccupied (because its agonist is absent or because a blocker prevents activation), cells increase receptor synthesis, raising receptor number and sensitivity. Upregulation is clinically important for predicting rebound effects after abrupt withdrawal of receptor-blocking drugs.1016
Denervation Supersensitivity. When a tissue loses its autonomic innervation, it develops heightened sensitivity to exogenous catecholamines and other agonists, a phenomenon termed denervation supersensitivity. Multiple mechanisms contribute. First, denervation eliminates neuronal reuptake of norepinephrine (NE) via the norepinephrine transporter (NET), so exogenous NE or epi is not cleared from the neuroeffector junction and reaches higher local concentrations at the receptor. Second, loss of tonic agonist stimulation produces receptor upregulation, increasing receptor number and post-receptor signaling efficiency. Third, in some tissues, denervation alters receptor subtype expression, producing hypersensitivity to agonists not normally dominant at that site. Clinically, denervation supersensitivity occurs after heart transplantation (the transplanted heart is denervated and responds exaggeratedly to exogenous catecholamines and reduced clearance of circulating catecholamines), after surgical sympathectomy, and in progressive autonomic neuropathies (diabetes mellitus, amyloidosis, pure autonomic failure). It underlies the exaggerated blood pressure response to vasopressors seen in some patients with dysautonomia and the extreme hemodynamic lability of patients with high cervical spinal cord injuries during autonomic dysreflexia.17
Beta-blocker withdrawal: Chronic beta-1 AR blockade → receptor upregulation → abrupt withdrawal exposes upregulated receptors to endogenous catecholamines → rebound tachycardia, hypertension, angina exacerbation (potentially precipitating myocardial infarction in coronary artery disease). Taper beta-blockers over 1–2 weeks in stable patients; never abrupt discontinuation in ischemic heart disease. Clonidine withdrawal: Alpha-2 AR blockade of presynaptic receptors → NE release disinhibited after abrupt cessation → rebound hypertensive crisis. Mechanism: upregulation of postsynaptic alpha-1 receptors + loss of central sympatholysis. Management: restart clonidine or substitute another antihypertensive; IV labetalol or phentolamine for crisis. General principle: the magnitude of rebound is proportional to the degree of receptor upregulation, which is proportional to the duration and completeness of receptor blockade.
The receptor knowledge developed in the preceding sections becomes clinically powerful when applied systematically. Given any autonomic drug and its receptor targets, the organ-by-organ response is predictable from three pieces of information: which receptor subtype the drug activates or blocks, how that receptor is coupled in the target tissue, and what baseline autonomic tone that tissue carries. This section works through the most clinically important organ systems using this framework.
Heart. The dominant cardiac adrenergic receptor is beta-1 (Gs, increases cAMP, protein kinase A [PKA] phosphorylation of Ca2+ channels and phospholamban → positive inotropy, chronotropy, lusitropy). The dominant cardiac cholinergic receptor is M2 (Gi, decreases cAMP, G-protein-coupled inwardly rectifying potassium [GIRK] activation → negative chronotropy, dromotropy). Predicting: dobutamine (beta-1 agonist) → increases heart rate and contractility in cardiogenic shock. Metoprolol (beta-1 blocker) → slows heart rate, reduces contractility, useful in rate control and heart failure. Atropine (M2 blocker) → increases heart rate, useful in symptomatic bradycardia. Digoxin (indirectly increases vagal tone via AV node) → negative dromotropy. Beta-1 blockade is contraindicated in acute decompensated heart failure or high-degree AV block because it further reduces rate and contractility.10
Vasculature. Vascular smooth muscle tone is set by alpha-1 adrenergic receptor (AR) activation (Gq → vasoconstriction) and beta-2 AR activation (Gs → vasodilation). The vascular endothelium also expresses muscarinic M3 (M3) receptors (Gq → nitric oxide [NO] production → vasodilation). Predicting: phenylephrine (alpha-1 agonist) → pure vasoconstriction, increases diastolic blood pressure, reflex bradycardia from baroreceptor activation (used for nasal congestion and to treat hypotension without tachycardia). Albuterol (beta-2 agonist) at high doses → skeletal muscle vasodilation → fall in diastolic blood pressure, reflex tachycardia. Prazosin (alpha-1 antagonist) → vasodilation, first-dose hypotension particularly severe because standing unmasks reduced venous return; always start with lowest dose at bedtime.8
Airway. Bronchial smooth muscle tone is controlled by beta-2 ARs (Gs → bronchodilation) and M3 ARs (Gq → bronchoconstriction). Predicting: albuterol (beta-2 agonist) → bronchodilation (acute asthma). Ipratropium (M3 antagonist, quaternary amine, does not cross BBB) → bronchodilation by blocking bronchoconstriction; additive with beta-2 agonists; particularly effective in chronic obstructive pulmonary disease (COPD) where cholinergic tone is the main reversible component. Non-selective beta-blockers (propranolol) → block beta-2 ARs in airways → bronchoconstriction; absolutely contraindicated in asthma; use cardioselective beta-1 blockers (metoprolol) if beta-blockade is required in patients with reactive airway disease, though selectivity is not absolute at high doses.11
Eye. The iris dilator muscle is controlled by alpha-1 ARs (sympathetic, produces mydriasis). The iris sphincter and ciliary muscle are controlled by M3 ARs (parasympathetic; sphincter contraction produces miosis, ciliary muscle contraction produces accommodation for near vision). Predicting: phenylephrine eye drops (alpha-1 agonist) → mydriasis for fundoscopic examination without cycloplegia (accommodation preserved because ciliary muscle M3 not blocked). Tropicamide or cyclopentolate (M3 antagonists) → mydriasis and cycloplegia (both pupil dilation and loss of accommodation); used for refraction. Pilocarpine (M3 agonist) → miosis and ciliary muscle contraction, reduces intraocular pressure by opening trabecular meshwork drainage; used in angle-closure glaucoma. Timolol (beta-blocker, eye drops) → reduces aqueous humor production (beta-2 AR on ciliary epithelium).8
Bladder and Reproductive System. The bladder detrusor muscle is controlled by M3 ARs (Gq → contraction, voiding) and beta-3 ARs (Gs → relaxation, storage). The internal urethral sphincter is controlled by alpha-1 ARs (Gq → contraction, continence). Predicting: M3 antagonists (oxybutynin, solifenacin, darifenacin) → reduce detrusor overactivity (overactive bladder) but cause dry mouth (M3 in salivary glands), constipation (M3 in GI), and cognitive effects (muscarinic M1 [M1] receptors in brain, particularly with oxybutynin which crosses the blood-brain barrier [BBB]); trospium (quaternary amine, minimal blood-brain barrier [BBB] penetration) reduces central nervous system (CNS) effects. Mirabegron (beta-3 agonist) → relaxes detrusor during storage phase; avoids anticholinergic side effects. Alpha-1 antagonists (tamsulosin, silodosin) → relax bladder neck and prostate → improved urine flow in benign prostatic hyperplasia (BPH). In the uterus, beta-2 ARs mediate relaxation; beta-2 agonists (terbutaline, ritodrine) are used as tocolytics to arrest premature labor.1112
Muscarinic: M1/M3 couple Gq (PLC → IP3/DAG → Ca2+/PKC); M2/M4 couple Gi (inhibit AC, activate GIRK). M2 = heart rate control and presynaptic autoreceptor; M3 = smooth muscle contraction and glandular secretion. Nicotinic: pentameric LGICs; NM (alpha1:beta1:delta:epsilon) at NMJ; NN (alpha3:beta4) at ganglia; CNS (alpha4:beta2, alpha7). Adrenergic: alpha-1 (Gq, vasoconstriction); alpha-2 (Gi, presynaptic feedback, central sympatholysis); beta-1 (Gs, cardiac stimulation); beta-2 (Gs, bronchodilation, vasodilation); beta-3 (Gs, bladder relaxation, lipolysis). Dopamine: D1-like (Gs, renal vasodilation, natriuresis; fenoldopam); D2-like (Gi, prolactin inhibition, CTZ emesis; antipsychotics block D2). Regulation: GRK/beta-arrestin mediate homologous desensitization → receptor internalization; chronic blockade → upregulation → rebound on withdrawal; denervation supersensitivity from upregulation plus loss of NET clearance.
Caulfield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50(2):279-290.
Harvey RD, Belevych AE. Muscarinic regulation of cardiac ion channels. Br J Pharmacol. 2003;139(6):1074-1084.
doi:10.1038/sj.bjp.0705338Eglen RM. Muscarinic receptor subtype pharmacology and physiology. Prog Med Chem. 2005;43:105-136.
doi:10.1016/S0079-6468(05)43004-0Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov. 2007;6(9):721-733.
doi:10.1038/nrd2379Sine SM. End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. Physiol Rev. 2012;92(3):1189-1234.
doi:10.1152/physrev.00015.2011Naguib M, Lien CA, Aker J. Neuromuscular physiology and pharmacology. In: Miller RD, ed. Miller's Anesthesia. 8th ed. Philadelphia: Elsevier Saunders; 2015:423-468.
Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295-2303.
doi:10.1056/NEJMra0809890Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147(Suppl 2):S88-S119.
doi:10.1038/sj.bjp.0706619Brede M, Philipp M, Knaus A, Muthig V, Hein L. Alpha2-adrenergic receptor subtypes — novel functions uncovered in gene-targeted mouse models. Biol Cell. 2004;96(5):343-348.
doi:10.1016/j.biolcel.2004.03.006Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101(5):558-569.
doi:10.1161/01.CIR.101.5.558Johnson M. Molecular mechanisms of beta2-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol. 2006;117(1):18-24.
doi:10.1016/j.jaci.2005.11.012Andersson KE. Beta-adrenoceptors and their role in the regulation of lower urinary tract function. Acta Pharmacol Sin. 2022;43(11):2741-2751.
doi:10.1038/s41401-022-00934-2Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev. 2000;24(1):125-132.
doi:10.1016/S0149-7634(99)00063-9Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-1401.
doi:10.1056/NEJMoa1402670Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38.
doi:10.1177/070674370204700106Lohse MJ, Benovic JL, Caron MG, Lefkowitz RJ. Multiple pathways of rapid beta2-adrenergic receptor desensitization: delineation with specific inhibitors. J Biol Chem. 1990;265(6):3202-3211.
doi:10.1016/S0021-9258(19)39750-0Wehrwein EA, Orer HS, Barman SM. Overview of the anatomy, physiology, and pharmacology of the autonomic nervous system. Compr Physiol. 2016;6(3):1239-1278.
doi:10.1002/cphy.c150037